Zusammenfassung
Das histologische Grading ist die älteste zellorientierte Methode zur Beurteilung der Tumorbiologie und Prognose beim Mammakarzinom. Dieser Übersichtsartikel gibt neben einem historischen Rückblick detaillierte und für die Praxis gedachte Hinweise zum histologischen Grading. Es wird außerdem erörtert, weshalb auch noch im Zeitalter der molekularen Pathologie der genauen Bestimmung des histologischen Grades weiterhin große Bedeutung zukommt.
Abstract
From a historical perspective, histological grading was the earliest cell-based method for assessing tumor biology and the prognosis of breast cancer. This review article provides detailed and practical instructions for grading of breast cancer in routine diagnostics. Furthermore, the increasing relevance of precise histological grading in the era of molecular pathology is discussed.
Literatur
Conard NJ, Malina M, Munzel SC (2009) New flutes document the earliest musical tradition in southwestern Germany. Nature 460:737–740
Hansemann D (1892) Ueber die Anaplasie der Geschwulstzellen und die asymmetrische Mitose. Virchows Arch Pathol Anat Physiol Klin Med 129:436–449
Sistrunk WE, Maccarty WC (1922) Life expectancy following radical amputation for carcinoma of the breast: A clinical and pathologic study of 218 cases. Ann Surg 75:61–69
Kaiser P, Karrer K (1972) Steinthal- oder TNM-System beim Mammakarzinom. Z Krebsforsch 77:274–278
Greenough RB (1925) Varying degrees of malignancy in cancer of the breast. J Cancer Res 9:453–463
Patey DH, Scarff RW (1928) Histology in the prognosis of carcinoma of the breast. Lancet 211:801–804
Bloom HJ, Richardson WW (1957) Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11:359–377
Stenkvist B, Westman-Naeser S, Vegelius J, Holmquist J, Nordin B et al (1979) Analysis of reproducibility of subjective grading systems for breast carcinoma. J Clin Pathol 32:979–985
Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5):403–410
Elston CW, Ellis IO (2002) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 41(3a):151–152
Longacre TA, Ennis M, Quenneville LA, Bane AL, Bleiweiss IJ et al (2006) Interobserver agreement and reproducibility in classification of invasive breast carcinoma: an NCI breast cancer family registry study. Mod Pathol 19:195–207
Weigelt B, Reis-Filho JS (2009) Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol 6:718–730
Perou CM, Sorlie T, Eisen MB, Rijn M van de, Jeffrey SS et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752
Lakhani SR, Ellis I, Schnitt S, Tan PH, Vijver M van de (2012) WHO classification of tumours of the breast. International Agency for Research on Cancer, Lyon
Robbins P, Pinder S, Klerk N de, Dawkins H, Harvey J et al (1995) Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol 26:873–879
Dabbs D (2012) Breast pathology. Elsevier Saunders, Philadelphia
Kronqvist P, Kuopio T, Collan Y (2000) Morphometric grading of breast cancer: thresholds for tubular differentiation. Br J Cancer 82:1656–1661
Gluz O, Nitz U, Christgen M, Kates RE, Shak S et al (2016) The WSG phase III planB trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment. J Clin Oncol doi:10.1200/JCO.2015.63.5383
Wasielewski R von, Klopper K, Luck HJ, Kreipe H (2006) Improvement of breast cancer grading in punch biopsies: grading with the Ki-67 marker. Pathologe 27:337–345
Kronqvist P, Kuopio T, Collan Y (1998) Morphometric grading of invasive ductal breast cancer. I. Thresholds for nuclear grade. Br J Cancer 78:800–805
Rosen PP (2008) Rosen’s breast pathology, 3. Aufl. Lippincott Williams & Wilkins, Dover
Mengel M, Wasielewski R von, Wiese B, Rudiger T, Muller-Hermelink HK, Kreipe H (2002) Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial. J Pathol 198:292–299
Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC et al (2011) Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 103:1656–1664
Polley MY, Leung SC, Gao D, Mastropasqua MG, Zabaglo LA et al (2015) An international study to increase concordance in Ki67 scoring. Mod Pathol 28(6):778–786
Christgen M, Ahsen S von, Christgen H, Langer F, Kreipe H (2015) The region-of-interest size impacts on Ki67 quantification by computer-assisted image analysis in breast cancer. Hum Pathol 46:1341–1349
Papadimitriou M, Kaptanis S, Polymeropoulos E, Mitsopoulos G, Stogiannis D et al (2015) Nuclear grade plus proliferation grading system for invasive ductal carcinoma of the breast: validation in a tertiary referral hospital cohort. Am J Clin Pathol 144:837–843
Abdel-Fatah TM, Powe DG, Agboola J, Adamowicz-Brice M, Blamey RW et al (2010) The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers. J Pathol 220:419–434
Abdel-Fatah TM, Powe DG, Ball G, Lopez-Garcia MA, Habashy HO et al (2010) Proposal for a modified grading system based on mitotic index and Bcl2 provides objective determination of clinical outcome for patients with breast cancer. J Pathol 222:388–399
Louwman MW, Vriezen M, Beek MW van, Nolthenius-Puylaert MC, Sangen MJ van der et al (2007) Uncommon breast tumors in perspective: incidence, treatment and survival in the Netherlands. Int J Cancer 121:127–135
Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN et al (2008) Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol 26:3006–3014
Erber R, Gluz O, Brunner N, Kreipe HH, Pelz E et al (2015) Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial. Breast Cancer Res Treat 150:279–288
Rakha EA, El-Sayed ME, Menon S, Green AR, Lee AH, Ellis IO (2008) Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast. Breast Cancer Res Treat 111:121–127
Daveau C, Baulies S, Lalloum M, Bollet M, Sigal-Zafrani B et al (2014) Histological grade concordance between diagnostic core biopsy and corresponding surgical specimen in HR-positive/HER2-negative breast carcinoma. Br J Cancer 110:2195–2200
Kwok TC, Rakha EA, Lee AH, Grainge M, Green AR et al (2010) Histological grading of breast cancer on needle core biopsy: the role of immunohistochemical assessment of proliferation. Histopathology 57:212–219
Pinder SE, Provenzano E, Earl H, Ellis IO (2007) Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapy. Histopathology 50:409–417
Pierga JY, Mouret E, Laurence V, Dieras V, Savigioni A et al (2003) Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer. the role of clinical response. Eur J Cancer 39:1089–1096
Langer F, Luck HJ, Kreipe HH (2004) Morphological response to therapy of breast carcinoma. Pathologe 25:455–460
Sinn HP, Schmid H, Junkermann H, Huober J, Leppien G et al (1994) Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy. Geburtshilfe Frauenheilkd 54:552–558
Bossuyt V, Provenzano E, Symmans WF, Boughey JC, Coles C et al (2015) Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. Ann Oncol doi:10.1093/annonc/mdv161
Dalton LW, Page DL, Dupont WD (1994) Histologic grading of breast carcinoma. A reproducibility study. Cancer 73:2765–2770
Frierson HF Jr, Wolber RA, Berean KW, Franquemont DW, Gaffey MJ et al (1995) Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma. Am J Clin Pathol 103:195–198
Davis BW, Gelber RD, Goldhirsch A, Hartmann WH, Locher GW et al (1986) Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Cancer 58:2662–2670
Paik S, Shak S, Tang G, Kim C, Baker J et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
M. Christgen, F. Länger und H. Kreipe geben an, dass kein Interessenkonflikt besteht.
Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.
Additional information
Schwerpunktherausgeber
C. Wittekind, Leipzig
Rights and permissions
About this article
Cite this article
Christgen, M., Länger, F. & Kreipe, H. Histologisches Grading beim Mammakarzinom. Pathologe 37, 328–336 (2016). https://doi.org/10.1007/s00292-016-0182-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00292-016-0182-8